Welcome to our dedicated page for Alnylam Pharmaceuticals news (Ticker: ALNY), a resource for investors and traders seeking the latest updates and insights on Alnylam Pharmaceuticals stock.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) regularly issues news on its RNA interference (RNAi) therapeutics, commercial performance, pipeline progress, and corporate developments. As a company that has led the RNAi field from discovery to approved medicines, its announcements often highlight data from pivotal trials, regulatory milestones, and updates on marketed products such as AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO.
Investors following ALNY news can expect detailed coverage of clinical results across multiple therapeutic areas, including transthyretin‑mediated amyloidosis (ATTR), hypertension, bleeding disorders, neurological diseases, and metabolic conditions. Recent releases have described post hoc analyses from the HELIOS‑B Phase 3 study of AMVUTTRA in ATTR‑CM and hATTR‑PN, showing effects on gastrointestinal events, cardiac structure and function, and renal outcomes, as well as broader safety and efficacy profiles.
Alnylam’s news flow also includes financial and strategic updates. The company reports quarterly and annual net product revenues, trends in its TTR and rare disease franchises, and guidance associated with frameworks such as its Alnylam P5x25 and Alnylam 2030 strategies. Filings and press releases have discussed convertible senior notes, a revolving credit facility, and partial repurchases of outstanding debt, providing context on capital structure and liquidity.
Operational and manufacturing developments are another key news theme. Alnylam has announced expansion of its Norton, Massachusetts siRNA manufacturing facility and the integration of its siRELIS enzymatic ligation platform, which has been accepted into the FDA’s Emerging Technology Program. Corporate governance items, such as changes to the Board of Directors and executive responsibilities, are also disclosed. For anyone tracking ALNY, this news stream offers insight into clinical milestones, commercial execution, manufacturing scale‑up, and strategic direction in RNAi therapeutics.
Alnylam Pharmaceuticals (Nasdaq: ALNY) will release its first-quarter 2021 financial results on April 29, 2021, before market opens. The company's management will hold a conference call at 8:30 am ET to discuss these results and future expectations. Interested parties can access the call via phone or through a live audio webcast on Alnylam's investor website. Alnylam aims to leverage its RNA interference (RNAi) platform to address various diseases, showcasing a strong pipeline and ongoing commitment to innovation in the biotech sector.
Alnylam Pharmaceuticals (Nasdaq: ALNY) reported positive interim results from its Phase 1 study of ALN-AGT, a novel RNAi therapeutic for hypertension. The study showed significant dose-dependent reductions in serum angiotensinogen (AGT) and blood pressure, with a maximum 17 mm Hg reduction in 24-hour systolic blood pressure at the 800 mg dose. The treatment was well tolerated, with most adverse events being mild. The company plans to initiate Phase 2 KARDIA studies in mid-2021, suggesting ALN-AGT may transform hypertension management.
Alnylam Pharmaceuticals (Nasdaq: ALNY) will present an overview at the 20th Annual Needham Virtual Healthcare Conference on April 13, 2021, at 1:30 pm ET. A live audio webcast will be accessible via the Investors section of the Company's website, with a replay available within 48 hours post-event. Alnylam is a leader in RNA interference (RNAi) therapeutics, aiming to transform treatments for rare genetic, cardio-metabolic, hepatic infectious, and CNS diseases. Their portfolio includes commercially available products like ONPATTRO, GIVLAARI, OXLUMO, and Leqvio.
Alnylam Pharmaceuticals (Nasdaq: ALNY) announced pivotal results from the ILLUMINATE-A Phase 3 study of lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1 (PH1). Published in NEJM, the study showed a significant 53.5% reduction in urinary oxalate levels compared to placebo at six months. Notably, 84% of patients on lumasiran reached normal or near-normal oxalate levels. The treatment had a favorable safety profile with no severe adverse events reported. OXLUMO is the first approved therapy for PH1, addressing a critical unmet medical need for patients.
Alnylam Pharmaceuticals (Nasdaq: ALNY) will present a company overview at the Stifel 3rd Annual CNS Day on April 1, 2021, at 11:00 am ET. A live audio webcast will be accessible via the Investors section of Alnylam's website, with a replay available within 48 hours. Alnylam is a leader in RNA interference therapeutics, focusing on innovative medicines for rare genetic and CNS diseases. They have launched products like ONPATTRO and are advancing multiple investigational medicines under the Alnylam P5x25 strategy.
Alnylam Pharmaceuticals (Nasdaq: ALNY) announced the upcoming presentation of full 9-month results from the HELIOS-A Phase 3 study of vutrisiran at the AAN Virtual Annual Meeting, scheduled for April 17-22. Vutrisiran is an investigational RNAi therapeutic for hereditary ATTR amyloidosis. This milestone follows the positive topline results previously reported in January. The company aims to submit a U.S. regulatory filing for vutrisiran in early 2021. The presentation will also feature updates from ongoing studies on ONPATTRO and GIVLAARI.
Alnylam Pharmaceuticals (Nasdaq: ALNY) has published its first Corporate Responsibility (CR) Summary, outlining its environmental, social, and governance (ESG) standards. Key commitments include increasing minority participation in clinical trials, promoting female leadership, and enhancing employee support programs. The report emphasizes Alnylam's dedication to sustainability and accountability, led by a new CR Committee. It marks a significant step toward the company's vision of becoming a top 5 biotech firm while adhering to its core values.
Soleo Health has joined the treatment center directory for GIVLAARI (givosiran), enabling it to administer this FDA-approved therapy for adults with Acute Hepatic Porphyria (AHP). GIVLAARI is the first approved treatment for AHP, which causes the buildup of neurotoxins. Soleo Health offers injections in-home or at its infusion centers, utilizing its experience in specialty pharmacy. This partnership enhances Soleo's portfolio in treating rare diseases and utilizes SoleMetrics to collect valuable patient data over time.
Alnylam Pharmaceuticals (Nasdaq: ALNY) will present at three upcoming virtual conferences. The events are the Cowen 41st Annual Healthcare Conference on March 1 at 2:40 pm ET, the H.C. Wainwright Global Life Sciences Conference on March 9 at 7:00 am ET, and the Barclays Global Healthcare Conference on March 10 at 1:15 pm ET. Each presentation will have a live audio webcast available on the Company’s website, with replays accessible within 48 hours.
Alnylam specializes in RNA interference therapeutics aimed at treating various severe diseases.
Alnylam Pharmaceuticals (Nasdaq: ALNY) announced a company overview presentation at the 10th Annual SVB Leerink Global Healthcare Conference, scheduled for February 25, 2021, at 11:20 am ET. A live audio webcast will be accessible on the Investors section of Alnylam's website, with a replay available 48 hours post-event.
Alnylam is a leader in RNA interference therapeutics, developing innovative medicines for various diseases. Its current products include ONPATTRO, GIVLAARI, and OXLUMO, among others.